Novel Genetic Causes of Pituitary Adenomas

Abstract

Recently, a number of novel genetic alterations have been identified that predispose individuals to pituitary adenomas. Clinically relevant pituitary adenomas are relatively common, present in 0.1% of the general population. They are mostly benign monoclonal neoplasms that arise from any of the five hormone-secreting cell types of the anterior lobe of the pituitary gland, and cause disease due to hormonal alterations and local space-occupying effects. The pathomechanism of pituitary adenomas includes alterations in cell-cycle regulation and growth factor signaling, which are mostly due to epigenetic changes; somatic and especially germline mutations occur more rarely. A significant proportion of growth hormone- and adrenocorticotrophin-secreting adenomas have activating somatic mutations in the GNAS and USP8 genes, respectively. Rarely, germline mutations predispose to pituitary tumorigenesis, often in a familial setting. Classical tumor predisposition syndromes include multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4) syndromes, Carney complex, and McCune-Albright syndrome. Pituitary tumors have also been described in association with neurofibromatosis type 1, DICER1 syndrome, and SDHx mutations. Pituitary adenomas with no other associated tumors have been described as familial isolated pituitary adenomas. Patients with AIP or GPR101 mutations often present with pituitary gigantism either in a familial or simplex setting. GNAS and GPR101 mutations that arise in early embryonic age can lead to somatic mosaicism involving the pituitary gland and resulting in growth hormone excess. Senescence has been suggested as the key mechanism protecting pituitary adenomas turning malignant in the overwhelming majority of cases. Here we briefly summarize the genetic background of pituitary adenomas, with an emphasis on the recent developments in this field. Clin Cancer Res; 22(20); 5030-42. ©2016 AACR SEE ALL ARTICLES IN THIS CCR FOCUS SECTION, "ENDOCRINE CANCERS REVISING PARADIGMS".

Identification of a novel somatic mutation of POU6F2 by whole‐genome sequencing in prolactinoma

“…Thus, we performed whole‐genome sequencing on matched tumor and normal blood samples from a patient with aggressive prolactinoma with severe invasion and surrounding bone destruction, aiming to identify somatic genetic alterations. We found that prolactinomas have a low mutational burden, as reflected by their benign nature (Caimari & Korbonits, ; Song et al, ). In addition, we identified novel somatic mutations in the POU domain, class 6, transcription factor 2 ( POU6F2 ) gene (OMIM, *609062, NM_001166018.2: c. 839 C>T; c. 875A>G).…”

‘If there were water we should stop and drink’: neurofibromatosis presenting with diabetes insipidus

“…Pituitary abnormalities, including both pituitary adenoma and lymphocytic hypophysitis, have been rarely described in patients with NF1, although recognition is increasing 3. Attention to the suprasellar region, in addition to the brain tissue, and orbits, on brain imaging of patients with NF1 is advised.…”

Sella turcica measurements on lateral cephalograms of patients with neurofibromatosis type 1

“…gynaecomastia, may develop without detectable hormone imbalance leading the investigators to the conclusion endocrine diagnostics appear to be unnecessary in these patients [99]. Furthermore, the putative causal relation between the rare case for primary pituitary adenoma and NF1 is presently unclear [100]. Table 20 (Tab.…”